<![CDATA[Genmab — Marts 2021]]>GB det var hvad Jan fortalte børsen quote : To produkter skinner
Jan van de Winkel er enig.

“Ja. Fordobling eller måske endda en tredobling, afhængig af hvilke produkter på hvilke markeder. Jeg fremhævede to i går. Epcoritamab og PD-L1x4-1BB, som begge vil være banebrydende på deres markeder,” siger han og lover en byge af nye forsøgsdata i løbet af 2021.

Han mener, at to produkter når markedet i 2021, og kræftmidlet epcoritamab, som er fundamentet i kæmpeaftalen med Abbvie til en værdi op mod

]]>https://dev.proinvestor.com/forum/topic/451552/genmab-marts-2021RSS for NodeTue, 09 Jun 2026 16:12:02 GMTMon, 01 Mar 2021 04:35:29 GMT60<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 14:10:27 GMT]]>For første gang siden 2008 er stort set alle Proinvestors annoncepladser udsolgt. Det er de nu og resten af foråret.
I påsken arbejder vi videre på at gøre dele af websitet responsivt med større mobilvenlighed.
Tak for et utal af indlæg i debat og chat. Tak for donationer. God påske til alle. BH Helge 🙂

]]>https://dev.proinvestor.com/forum/post/10239907https://dev.proinvestor.com/forum/post/10239907Wed, 31 Mar 2021 14:10:27 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:18:53 GMT]]>Onsdagens aktier: Ambu og grønne aktier til tops i påskefest på børsen:
https://www.proinvestor.com/investornyt/673703/onsdagens-aktier-ambu-og-gronne-aktier-til-tops-i-paskefest-pa-borsen

]]>https://dev.proinvestor.com/forum/post/10239906https://dev.proinvestor.com/forum/post/10239906Wed, 31 Mar 2021 13:18:53 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:16:48 GMT]]>Jeps..det er nok det som skal drive kursen det næste stykke tid.

]]>https://dev.proinvestor.com/forum/post/10239904https://dev.proinvestor.com/forum/post/10239904Wed, 31 Mar 2021 13:16:48 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:13:33 GMT]]>Q1 har sidste dag. Måske der bliver rokeret rundt i porteføljerne rundt omkring. Det vil være godt, hvis biotek blev moderne igen. 😉

]]>https://dev.proinvestor.com/forum/post/10239901https://dev.proinvestor.com/forum/post/10239901Wed, 31 Mar 2021 13:13:33 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:05:46 GMT]]>🙂

]]>https://dev.proinvestor.com/forum/post/10239905https://dev.proinvestor.com/forum/post/10239905Wed, 31 Mar 2021 13:05:46 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:03:03 GMT]]>Pyt Helge..bare den stiger...

]]>https://dev.proinvestor.com/forum/post/10239902https://dev.proinvestor.com/forum/post/10239902Wed, 31 Mar 2021 13:03:03 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:02:29 GMT]]>God påske til alle:-)

]]>https://dev.proinvestor.com/forum/post/10239903https://dev.proinvestor.com/forum/post/10239903Wed, 31 Mar 2021 13:02:29 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:02:21 GMT]]>"Opad" er bedre. 😄

]]>https://dev.proinvestor.com/forum/post/10239908https://dev.proinvestor.com/forum/post/10239908Wed, 31 Mar 2021 13:02:21 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:01:40 GMT]]>Det går fremad..:-)

]]>https://dev.proinvestor.com/forum/post/10239898https://dev.proinvestor.com/forum/post/10239898Wed, 31 Mar 2021 13:01:40 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 13:01:24 GMT]]>Luk 2.088 (+3,37%). 🙂

]]>https://dev.proinvestor.com/forum/post/10239900https://dev.proinvestor.com/forum/post/10239900Wed, 31 Mar 2021 13:01:24 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 12:42:35 GMT]]>Jeps 😄

]]>https://dev.proinvestor.com/forum/post/10239909https://dev.proinvestor.com/forum/post/10239909Wed, 31 Mar 2021 12:42:35 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 12:42:31 GMT]]>US noteringen er fint med. +3,75%

]]>https://dev.proinvestor.com/forum/post/10239899https://dev.proinvestor.com/forum/post/10239899Wed, 31 Mar 2021 12:42:31 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 12:36:53 GMT]]>Lad os starte en storbrand

]]>https://dev.proinvestor.com/forum/post/10239896https://dev.proinvestor.com/forum/post/10239896Wed, 31 Mar 2021 12:36:53 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 12:20:32 GMT]]>Der er kommet en smule ild i raketten..på trods af US åbning:-)

]]>https://dev.proinvestor.com/forum/post/10239895https://dev.proinvestor.com/forum/post/10239895Wed, 31 Mar 2021 12:20:32 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 07:49:27 GMT]]>Aktier/middag: Vestas og Ambu trækker C25 mod påskeferie i grønt
https://www.proinvestor.com/investornyt/673683/aktier-middag-vestas-og-ambu-traekker-c25-mod-paskeferie-i-gront

]]>https://dev.proinvestor.com/forum/post/10239897https://dev.proinvestor.com/forum/post/10239897Wed, 31 Mar 2021 07:49:27 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 06:33:15 GMT]]>"US: Amerikanske biotech aktier viser fortsat svaghed, trækker Genmab med ned" https://www.proinvestor.com/investornyt/673677/us-amerikanske-biotech-aktier-viser-fortsat-svaghed-traekker-genmab-med-ned

]]>https://dev.proinvestor.com/forum/post/10239893https://dev.proinvestor.com/forum/post/10239893Wed, 31 Mar 2021 06:33:15 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:42:10 GMT]]>it is nice to see Sahin on top of these; he gets a lot of press atm offcourse. he was also a co-author of that AACR abstract he mentioned at 09.23 (not ASCR as written by translator)

]]>https://dev.proinvestor.com/forum/post/10239890https://dev.proinvestor.com/forum/post/10239890Wed, 31 Mar 2021 05:42:10 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:33:22 GMT]]>Thx EL

]]>https://dev.proinvestor.com/forum/post/10239891https://dev.proinvestor.com/forum/post/10239891Wed, 31 Mar 2021 05:33:22 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:24:39 GMT]]>A: Ugur Sahin

Yeah, the trimer formation is - indeed the trimer formation is important for the conditional activation of the 4-1BB and with 100 microgram we have the sweet spot of PD-L1 or PD-1 blockade, plus trimer formation in a sufficiently long time. So we exploit here the optimal activation or functions of both arms of the antibody. And this is also in line with objective responses that we have observed with this component which are - which seem to be associated with this dose window.

]]>https://dev.proinvestor.com/forum/post/10239889https://dev.proinvestor.com/forum/post/10239889Wed, 31 Mar 2021 05:24:39 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:24:18 GMT]]>Q: And then maybe on your PD-L1x4-1BB bispecific, Genmab mentioned one of the reasons they selected the 100 million [ph] dose, they wanted to have optimal trimer formation. And that kind of translates to about 60% to 70% occupancy for the PD-L1. How important is that formation of a trimer and why not target a higher PD-L1 occupancy from an efficacy perspective? Thank you.

]]>https://dev.proinvestor.com/forum/post/10239894https://dev.proinvestor.com/forum/post/10239894Wed, 31 Mar 2021 05:24:18 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:23:44 GMT]]>For BNT312, which conditionally targets CD4 Gen 4-1BB, we plan to present data from the ongoing Phase 1/2 trial in the second half of 2021. In addition, an extract [ph] highlighting preclinical data for BNT312 has been accepted for presentation at the upcoming ASCR meeting. The abstract [ph] describes the mechanism of action of conditional CD4 and 4-1BB activity to induce dendritic cell maturation and enhancement of T-cell activation and effector function.

]]>https://dev.proinvestor.com/forum/post/10239892https://dev.proinvestor.com/forum/post/10239892Wed, 31 Mar 2021 05:23:44 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:23:25 GMT]]>Given the unmet need for improved checkpoint immunotherapies, we remain very encouraged by the results presented at last year's SITC [ph] conference and seen to date and believes the product has significant potential across multiple oncology indications. We look forward to moving this program forward with Genmab.

]]>https://dev.proinvestor.com/forum/post/10239885https://dev.proinvestor.com/forum/post/10239885Wed, 31 Mar 2021 05:23:25 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:23:08 GMT]]>Moving to our next-generation checkpoint immunomodulators program, which is partnered with Genmab. We expect to present a data update in the second half of 2021 for the first-in-human Phase 1/2 trial of BNT311, also called GEN1046. BNT311 conditionally targets PD-L1 and 4-1BB and has the potential to be first in class.

]]>https://dev.proinvestor.com/forum/post/10239886https://dev.proinvestor.com/forum/post/10239886Wed, 31 Mar 2021 05:23:08 GMT<![CDATA[Reply to Genmab — Marts 2021 on Wed, 31 Mar 2021 05:22:42 GMT]]>BioNTech SE (BNTX) CEO Ugur Sahin on Q4 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4416873-biontech-se-bntx-ceo-ugur-sahin-on-q4-2020-results-earnings-call-transcript

]]>https://dev.proinvestor.com/forum/post/10239882https://dev.proinvestor.com/forum/post/10239882Wed, 31 Mar 2021 05:22:42 GMT